Home » Topics » Regulatory, BioWorld Science

Regulatory, BioWorld Science
RSS

FDA approves Skyrizi for moderate to severe plaque psoriasis

April 24, 2019

FDA approves Balversa for metastatic bladder cancer

April 15, 2019

FDA approves Dovato for treatment-naive HIV-1

April 9, 2019

CE mark for radioenhancer Hensify for locally advanced soft tissue sarcoma

April 8, 2019

Asceniv approved by FDA to treat humoral immunodeficiency disease

April 2, 2019

FDA approves Duaklir for maintenance treatment of COPD

April 1, 2019

Cimzia becomes the first and only FDA-approved treatment for nonradiographic axial spondyloarthritis

March 29, 2019

Foscavir approved in Japan to treat HHV-6 encephalitis

March 27, 2019

AnGes obtains conditional approval in Japan for HGF plasmid in critical limb ischemia

March 27, 2019

Revcovi approved in Japan for ADA deficiency

March 27, 2019

Popular Stories

Today's news in brief
BioWorld
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...
New mechanism of action identified for QC-6352
BioWorld Science
QC-6352 is a small molecule developed to inhibit the histone demethylase 4 (KDM4) that has shown potent antitumoral activity and which has a derivative named...
First-in-class pan-inflammasome blocker for hidradenitis suppurativa
BioWorld Science
Researchers from Paratus Sciences Corp. presented the preclinical profile of PS-1001, a novel pan-inflammasome inhibitor designed to prevent IL-1β and IL-18 release.
SCAN is core circuit affected in Parkinson’s disease
BioWorld
Parkinson’s disease is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder, and...